Using GEMM and PDX models of pancreatic cancer to identify new therapeutic opportunities in PDAC


Session type:

Owen Sansom1
1Cancer Research UK Beatson Institute, Glasgow, UK


Pancreatic cancer is a deadly disease where few therapies exist and limited improvements in standard of care have been made. I will give an overview of our current work using both genetically engineered mouse models (GEMM) that bear the mutations that occur in the human disease and patient derived xenografts (PDXs) to identify new therapeutic targets in pancreatic cancer.
Specifically I will give an overview of using these models to test the concepts of ‘exceptional responders’ and antimetastatic approaches in surgically resectable disease. Furthermore I will discuss exciting new opportunities to target the pancreatic cancer microenvironment.